TRK fusions are considered significant in the context of cancer because they represent actionable targets for therapy. The abnormal proteins produced by these genetic alterations can be specifically targeted by a new class of cancer drugs known as TRK inhibitors. This targeted therapy has shown substantial effectiveness in shrinking tumors and managing cancer progression across different types of cancers that harbor such fusions.
